Emergent jumps on FDA nod for smallpox vaccine for high-risk mpox cases

Emergent BioSolutions

30/08/2024 09:23

** Shares of Emergent BioSolutions  EBS.N  up 25.14 at
$11.19 premarket
    ** U.S. Food and Drug Administration (FDA) has approved
expanded use of EBS ACAM2000 smallpox vaccine to include people
at high risk for mpox infection
    ** FDA's approval follows Emergent's application for an
Emergency Use Listing of ACAM2000 vaccine with the World Health
Organization 
    ** ACAM2000 has more known side effects and risks than
Danish biotech Bavarian Nordic A/S's  BAVA.CO  Jynneos vaccine,
which is approved in the United States for both smallpox and
mpox
    ** Earlier this month, WHO declared mpox a global public
health emergency for the second time in two years 
    ** EBS has nearly quadrupled in value this year despite
losing ~30% of its value this month

 (Reporting by Medha Singh)
 ((medha.singh@thomsonreuters.com))